PIK3CA
Universal Cellular Machinery · Phosphorylation & Kinase Signaling Cascades
How can a PIK3CA change affect growth in only some tissues?
PIK3CA makes the catalytic component of a growth-signaling enzyme called PI3K. Changes acquired after conception can be present in only a subset of cells, making the sampled tissue important to interpretation.
- Common Gene Name
- phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
- NCBI Gene ID
- 5290
- Chromosome
- 3
Clinical Evidence Status
Disease evidence limited or conflictingTumor or drug-label biomarker context
These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.
Answer Sources
Explore supporting evidence (16 records)
| Condition or drug | Evidence | Grade / status | Context | Source |
|---|---|---|---|---|
| hereditary breast carcinoma | ClinGen gene-disease validity | Refuted | Autosomal dominant | View source 2023-12-21 |
| familial ovarian cancer | ClinGen gene-disease validity | No Known Disease Relationship | Autosomal dominant | View source 2017-02-08 |
| Bladder cancer | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2020-02 | |
| Cowden syndrome | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2020-02 | |
| Klippel-Trenaunay syndrome | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2020-02 | |
| Epidermal nevus | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2020-02 | |
| Megalencephaly-capillary malformation syndrome | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2020-02 | |
| Head and neck squamous cell carcinoma | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2020-02 | |
| Ovarian cancer | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2020-02 | |
| Lung cancer | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2020-02 | |
| Cholangiocarcinoma | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2020-02 | |
| Alpelisib (3) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Capivasertib (4) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Inavolisib (3) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Palbociclib (3) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Fam-Trastuzumab Deruxtecan-nxki (3) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.
← Back to Universal Cellular Machinery